How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
Delmas
P D
PD
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D018488:Bone Demineralization, Pathologic / Q000209:etiology / Q000517:prevention & control*; D001842:Bone and Bones / Q000473:pathology; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000503:physiopathology*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012306:Risk
D004965:Estrogen Antagonists; D020849:Raloxifene Hydrochloride; D019386:Alendronate